Regenerative medicine company Healios acquires assets from Athersys

  • Athersys to sell most assets to Healios in a $2 million deal
  • Stalking-horse asset-purchase agreement with Healios
  • Athersys to receive $2 million in the form of a credit bid
  • Athersys and its subsidiaries file for Chapter 11 bankruptcy

Athersys, a clinical-stage biotechnology company, has entered into a stalking-horse asset-purchase agreement with Healios, a regenerative medicine and cell therapy company. The agreement, valued at $2 million, includes the sale of all of Athersys’ assets, including contracts, personal property, inventory, and intellectual property. A stalking-horse sale process is in place, which means the purchase is conditional on no better offers being received. Athersys will receive the $2 million in the form of a credit bid. In addition, Athersys and its subsidiaries have filed for Chapter 11 bankruptcy in the Bankruptcy Court for the Northern District of Ohio.

Public Companies: Athersys (Unknown), Healios (Unknown)
Private Companies:
Key People:

Factuality Level: 8
Justification: The article provides factual information about Athersys selling its assets to Healios in an agreement valued at $2 million. It mentions the details of the asset-purchase agreement and the bankruptcy filing. However, it lacks additional context or analysis, making it somewhat limited in terms of providing a comprehensive understanding of the situation.

Noise Level: 7
Justification: The article provides relevant information about Athersys selling its assets to Healios, but it lacks in-depth analysis, evidence, and actionable insights. It mainly focuses on the transaction details and the bankruptcy filing without exploring the long-term implications or consequences for the company and its stakeholders.

Financial Relevance: Yes
Financial Markets Impacted: The sale of Athersys’ assets to Healios may impact the financial markets and companies involved in the regenerative medicine and cell therapy industry.

Presence of Extreme Event: No
Nature of Extreme Event: No
Impact Rating of the Extreme Event: No
Justification: The article discusses a financial transaction involving the sale of assets and the filing for Chapter 11 bankruptcy protection. While this event may have financial implications for Athersys and Healios, it does not describe an extreme event.

Reported publicly: www.marketwatch.com